Targeting 3D chromosomal architecture at the RANK loci to suppress myeloma-driven osteoclastogenesis.
Katja ThümmlerMark Ts WilliamsSusan KitsonShatakshi SoodMoeed AkbarJohn J ColeEwan HunterRichard SoutarCarl S GoodyearPublished in: Oncoimmunology (2022)
Bone disease represents a major cause of morbidity and mortality in Multiple Myeloma (MM); primarily driven by osteoclasts whose differentiation is dependent on expression of RANKL by MM cells. Notably, costimulation by ITAM containing receptors (i.e., FcγR) can also play a crucial role in osteoclast differentiation. Modeling the pathology of the bone marrow microenvironment with an ex vivo culture system of primary human multiple myeloma cells, we herein demonstrate that FcγR-mediated signaling, via staphylococcal protein A (SpA) IgG immune-complexes, can act as a critical negative regulator of MM-driven osteoclast differentiation. Interrogation of the mode-of-action revealed that FcγR-mediated signaling causes epigenetic modulation of chromosomal 3D architecture at the RANK promoter; with altered spatial orientation of a proximal super enhancer. Combined this leads to substantial down-regulation of RANK at a transcript, protein, and functional level. These observations shed light on a novel mechanism regulating RANK expression and provide a rationale for targeting FcγR-signaling for the amelioration of osteolytic bone pathology in disease.
Keyphrases
- bone loss
- multiple myeloma
- induced apoptosis
- binding protein
- bone marrow
- poor prognosis
- cell cycle arrest
- dna methylation
- transcription factor
- gene expression
- bone mineral density
- endothelial cells
- stem cells
- cancer therapy
- soft tissue
- clinical trial
- copy number
- endoplasmic reticulum stress
- genome wide
- cell death
- methicillin resistant staphylococcus aureus
- inflammatory response
- drug delivery
- newly diagnosed
- toll like receptor
- induced pluripotent stem cells
- body composition
- immune response
- postmenopausal women
- lps induced